ReviewNutrients2026
The Microbiota-Gut-Brain Axis in Obesity: Inflammation, Appetite Dysregulation, and Feeding Behavior.
Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Obesity is increasingly recognized as a disorder of bidirectional communication among the gut microbiota, immune system, and neural circuits controlling energy balance and feeding behavior. This review examines the associations and potential mechanistic links between obesity-associated dysbiosis, chronic low-grade inflammation, and impaired appetite regulation through interconnected peripheral and central pathways. We discuss how these signals reach the central nervous system (CNS), and promote microglial and astrocytic activation, impair leptin and insulin signaling, and disrupt hypothalamic POMC and AgRP/NPY neuronal networks. We also examine how microbial metabolites and structural components influence appetite through enteroendocrine hormones, vagal afferents, blood-brain barrier (BBB) integrity, and direct actions on neural and glial cells. Particular emphasis is placed on short-chain fatty acids, tryptophan-derived metabolites, bile acids, and lipopolysaccharide, as well as their effects on glucagon-like peptide-1 (GLP-1), peptide YY (PYY), serotonergic signaling, and mesolimbic reward pathways. Together, these findings support a bidirectional framework in which diet, microbiota function, immune signaling, and neural regulation may reinforce one another during obesity progression. However, the directionality and causal relevance of many of these relationships, particularly in humans, remain incompletely understood. Clarifying these microbiota-gut-brain interactions may identify new targets for restoring appetite control and interrupting obesity progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.